tiprankstipranks
INNOVATE Corp (VATE)
NYSE:VATE
Want to see VATE full AI Analyst Report?

INNOVATE Corp (VATE) AI Stock Analysis

268 Followers

Top Page

VATE

INNOVATE Corp

(NYSE:VATE)

Select Model
Select Model
Select Model
Neutral 55 (OpenAI - 5.2)
Rating:55Neutral
Price Target:
$16.50
▲(226.73% Upside)
Action:Reiterated
Date:06/12/26
The score is held back primarily by weak financial quality—persistent net losses and an extremely levered balance sheet with thin equity—despite strong recent cash generation. Technicals are a key offset, showing a sustained uptrend and constructive momentum. Earnings-call commentary adds moderate support from Infrastructure-led growth and improved EBITDA, but margin compression, segment weakness in Life Sciences/Spectrum, and rising debt keep risk elevated.
Positive Factors
Strong cash generation
Sustained trailing‑twelve‑month operating cash flow (~$206M) and free cash flow (~$175M) provide a durable internal funding source. This cash conversion supports working capital, funds capex or debt servicing, and gives the company flexibility to pursue restructuring or capital‑structure solutions despite accounting losses.
Negative Factors
Extremely high leverage
Very high debt relative to a thin equity base constrains financial flexibility and raises refinancing and covenant risks. Limited equity buffers amplify earnings or working‑capital volatility, making the company vulnerable to adverse cycles and increasing the need for sustained cash generation or external capital to stabilize the capital structure.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong cash generation
Sustained trailing‑twelve‑month operating cash flow (~$206M) and free cash flow (~$175M) provide a durable internal funding source. This cash conversion supports working capital, funds capex or debt servicing, and gives the company flexibility to pursue restructuring or capital‑structure solutions despite accounting losses.
Read all positive factors

INNOVATE Corp (VATE) vs. SPDR S&P 500 ETF (SPY)

INNOVATE Corp Business Overview & Revenue Model

Company Description
INNOVATE Corp. (VATE), a New York-based entity founded in 1994 and previously known as HC2 Holdings, Inc. until its name change in September 2021, manages a diverse range of subsidiaries operating within the infrastructure, life sciences, and spec...
How the Company Makes Money
null...

INNOVATE Corp Earnings Call Summary

Earnings Call Date:May 14, 2026
(Q1-2026)
|
% Change Since: |
Next Earnings Date:Aug 12, 2026
Earnings Call Sentiment Positive
The call reflects a predominantly positive operational story driven by a strong Infrastructure / DBMG performance that delivered outsized revenue (up 33% consolidated) and adjusted EBITDA improvement. Significant regulatory and clinical milestones at MediBeacon and international growth at R2 are constructive. However, meaningful challenges remain in smaller but important areas: Life Sciences revenues fell sharply (-48.4%), R2 is seeking external capital, Spectrum experienced advertising weakness and cancellations, DBMG saw ~140 bps gross margin compression, and consolidated debt increased due to PIK interest. Overall, the positive momentum in the company’s largest revenue driver and improved overall profitability outweighs the segment‑level headwinds, but capital structure and segment weaknesses warrant continued attention.
Positive Updates
Consolidated Revenue Growth
Consolidated revenues of $364.8 million in Q1 2026, an increase of 33% versus $274.2 million in Q1 2025, driven primarily by Infrastructure.
Negative Updates
Life Sciences Revenue Decline
Life Sciences revenue decreased 48.4% to $1.6 million from $3.1 million in Q1 2025, largely due to lower R2 Glacial FX and Glacial Rx unit sales in North America—necessitating capital raises to continue progression.
Read all updates
Q1-2026 Updates
Negative
Consolidated Revenue Growth
Consolidated revenues of $364.8 million in Q1 2026, an increase of 33% versus $274.2 million in Q1 2025, driven primarily by Infrastructure.
Read all positive updates
Company Guidance
Management’s guidance was largely qualitative and focused on improving 2026 visibility, continued Infrastructure momentum and pipeline-driven backlog growth, while they work on capital‑structure alternatives; key Q1 metrics referenced include consolidated revenue $364.8M (up 33% YoY), total adjusted EBITDA $19.7M (vs. $7.2M), net loss $17.2M or $1.29 per diluted share (vs. $24.8M, $1.89), cash $134.6M, and total debt $699M (up $11.8M); Infrastructure/DBMG exited Q1 with revenue $357.9M (up 35.1% YoY), adjusted EBITDA $23.0M, gross margin 14.2% (≈140 bps compression YoY), reported backlog $1.6B and adjusted backlog $1.8B; Life Sciences/R2 reported Q1 revenue $1.6M (down 48.4%), total demand $2.2M and a backlog of ≈160 systems (~$2M) and is seeking external capital; Spectrum had Q1 revenue $5.3M and adjusted EBITDA $0.7M but cited near‑term softness offset by regulatory tailwinds (applications for >60 LPT licenses, >25 Class A relocations) and potential commercial opportunities.

INNOVATE Corp Financial Statement Overview

Summary
Mixed fundamentals: revenue has re-accelerated and recent operating/free cash flow is strong (TTM operating cash flow ~$206M; free cash flow ~$175M), but profitability remains weak with ongoing net losses (TTM net margin ~-4.0%) and very thin margins. The balance sheet is the main drag, with extremely high leverage and very thin equity (~$611M debt vs. ~$10.8M equity), elevating refinancing and volatility risk.
Income Statement
38
Negative
Balance Sheet
18
Very Negative
Cash Flow
62
Positive
BreakdownTTMDec 2025Mar 2025Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue1.34B1.25B1.11B1.42B1.64B1.21B
Gross Profit194.80M182.20M208.80M216.00M221.40M183.70M
EBITDA66.20M57.90M74.00M63.10M62.80M31.80M
Net Income-52.90M-60.60M-34.60M-35.20M-35.90M-227.50M
Balance Sheet
Total Assets936.80M950.10M891.10M1.04B1.15B1.08B
Cash, Cash Equivalents and Short-Term Investments134.60M112.10M48.80M80.80M80.40M45.50M
Total Debt765.50M717.50M719.20M771.90M785.30M684.80M
Total Liabilities1.17B1.17B1.05B1.20B1.18B1.09B
Stockholders Equity-246.80M-230.80M-180.40M-165.50M-103.70M-84.30M
Cash Flow
Free Cash Flow175.30M120.50M-9.90M8.10M-30.20M65.40M
Operating Cash Flow206.20M146.60M9.10M26.50M-9.50M89.50M
Investing Cash Flow-28.30M-22.60M-13.90M23.20M-22.50M-299.20M
Financing Cash Flow-77.10M-61.20M-26.50M-49.40M68.10M17.80M

INNOVATE Corp Technical Analysis

Technical Analysis Sentiment
Positive
Last Price5.05
Price Trends
50DMA
12.65
Positive
100DMA
8.85
Positive
200DMA
6.94
Positive
Market Momentum
MACD
1.50
Positive
RSI
59.12
Neutral
STOCH
40.65
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VATE, the sentiment is Positive. The current price of 5.05 is below the 20-day moving average (MA) of 15.22, below the 50-day MA of 12.65, and below the 200-day MA of 6.94, indicating a bullish trend. The MACD of 1.50 indicates Positive momentum. The RSI at 59.12 is Neutral, neither overbought nor oversold. The STOCH value of 40.65 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for VATE.

INNOVATE Corp Risk Analysis

INNOVATE Corp disclosed 84 risk factors in its most recent earnings report. INNOVATE Corp reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

INNOVATE Corp Peers Comparison

Overall Rating
UnderperformOutperform
Sector (63)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
63
Neutral
$10.79B15.437.44%2.01%2.89%-14.66%
62
Neutral
$311.62M31.6614.45%1.11%19.86%-49.73%
59
Neutral
$9.94M-0.71-51.96%18.10%99.97%
55
Neutral
$228.09M-4.2222.84%25.37%-52.95%
47
Neutral
$147.96M-6.2237.16%-4.88%82.47%
47
Neutral
$16.22M-578.91%-21.47%-541.99%
* Industrials Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
VATE
INNOVATE Corp
16.72
11.36
211.94%
SUNE
SUNation Energy
2.41
0.70
40.94%
ESOA
Energy Services of America
16.70
6.27
60.05%
SHIM
Shimmick Corporation
3.66
2.00
120.48%
SKK
SKK Holdings Limited
4.38
-1.62
-27.00%
MSW
Ming Shing Group Holdings Limited
1.25
-3.04
-70.86%

INNOVATE Corp Corporate Events

Executive/Board ChangesShareholder Meetings
INNOVATE Corp Shareholders Back Board, Compensation and Auditor
Positive
Jun 11, 2026
At INNOVATE Corp.’s annual meeting of stockholders held on June 11, 2026, investors re-elected four directors—Avram A. Glazer, Warren H. Gfeller, Brian S. Goldstein and Amy M. Wilkinson—to serve until the 2027 annual meeting, sig...
Business Operations and StrategyM&A TransactionsPrivate Placements and Financing
INNOVATE Restructures Broadcasting Stake Through CONX Merger
Positive
Jun 1, 2026
On May 29, 2026, INNOVATE Corp. subsidiaries HC2 Broadcasting and HC2 Broadcasting Holdco entered into a merger agreement with CONX Corp. that will see CONX gain a controlling stake in Broadcasting, with CONX expected to hold about 75% and INNOVAT...
Business Operations and StrategyFinancial Disclosures
INNOVATE Corp Posts Strong Q1 2026 Revenue Growth
Positive
May 14, 2026
On May 14, 2026, INNOVATE Corp. reported first-quarter 2026 consolidated revenue of $364.8 million, up 33% year over year, driven largely by a 35.1% revenue jump at infrastructure unit DBM Global to $357.9 million. The company narrowed its net los...
Business Operations and StrategyDividends
INNOVATE Corp Subsidiary DBM Global Declares Cash Dividend
Positive
Apr 6, 2026
On April 6, 2026, INNOVATE Corp. announced that its steel construction subsidiary DBM Global Inc. will pay a cash dividend of about $3 million, or $0.78 per share, to stockholders of record as of April 13, 2026, with payment scheduled for April 28...
Business Operations and StrategyProduct-Related Announcements
INNOVATE Corp Gains EU CE Mark for MediBeacon Devices
Positive
Mar 31, 2026
On March 31, 2026, INNOVATE Corp. reported that its equity-method investee MediBeacon received European Union CE Mark certification under the EU Medical Device Regulation for its TGFR Monitor and TGFR Reusable Sensor, two Class IIa devices used in...
Business Operations and StrategyFinancial Disclosures
INNOVATE Corp Reports Strong Q4 2025 Revenue Growth
Positive
Mar 26, 2026
INNOVATE Corp. reported on March 26, 2026 that its fourth-quarter 2025 revenue rose 61.7% year-on-year to $382.7 million and full-year 2025 revenue increased 12.5% to $1.25 billion, driven mainly by its Infrastructure arm, while net loss attributa...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jun 12, 2026